A randomized, placebo-controlled, double-blind, dose-ranging, multicenter, phase IIb clinical trial to investigate the efficacy and safety of allo-APZ2-CVU on wound healing of therapy-resistant chronic venous ulcer (CVU)
Latest Information Update: 27 Sep 2024
At a glance
- Drugs APZ 2 (Primary)
- Indications Varicose ulcer
- Focus Adverse reactions; Therapeutic Use
- Sponsors RHEACELL
- 13 Sep 2024 Status changed from recruiting to active, no longer recruiting.
- 26 Oct 2023 Planned End Date changed from 1 Aug 2023 to 1 Jun 2026.
- 26 Oct 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Jun 2026.